VIVUS, Inc.
VIVUS Reports 2008 Fourth Quarter and Full-Year Financial Results
Published in Obesity and Diabetes Week, March 23rd, 2009
“In 2008, VIVUS made excellent progress with the clinical development of Qnexa, our novel, investigational drug in Phase 3 trials for the treatment of obesity and in Phase 2 trials for the treatment of type 2 diabetes,” stated Leland Wilson, president and chief executive officer of VIVUS. “In addition, Qnexa has been well tolerated in our studies completed to date. We look forward to obtaining the results from our EQUIP and CONQUER pivotal Phase 3...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week
More Articles from Obesity and Diabetes Week
- Cedars-Sinai Medical Center
Older patients with 1 type of heart failure may receive little or no benefit from drugs - Georgia State University
Reducing suicidal behaviors among adolescents - The Peninsula College of Medicine and Dentistry
New study of human pancreases links virus to cause of type 1 diabetes - Diabetes
New diabetes study findings have been reported from M.M.J. Nielen et al - Diabetes
Researchers from University of Melbourne publish new studies and findings in the area of diabetes - Life Sciences
Research on life sciences discussed by scientists at University of Milan - More from this issue of Obesity and Diabetes Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
